1. Targeted next-generation sequencing in blast phase myeloproliferative neoplasms
by Terra L. Lasho, Mythri Mudireddy, Christy M. Finke, Curtis A. Hanson, Rhett P. Ketterling, Natasha Szuber, Kebede H. Begna, Mrinal M. Patnaik, Naseema Gangat, Animesh Pardanani, and Ayalew Tefferi
BloodAdv
Volume 2(4):
February 27, 2018
© 2018 by The American Society of Hematology

2. Terra L. Lasho et al. Blood Adv 2018;2:370-380
© 2018 by The American Society of Hematology

3. Molecular signature in 75 patients with blast phase MPN
Molecular signature in 75 patients with blast phase MPN. (A) stratification headed by driver mutations followed by most frequent mutations.
Molecular signature in 75 patients with blast phase MPN. (A) stratification headed by driver mutations followed by most frequent mutations. (B) Stratification headed by mutations that are overrepresented compared with historical data on chronic phase disease.
Terra L. Lasho et al. Blood Adv 2018;2:
© 2018 by The American Society of Hematology

4. Molecular signature in paired samples from chronic phase (CP) and blast phase (BP) disease in 19 patients with MPNs.
Molecular signature in paired samples from chronic phase (CP) and blast phase (BP) disease in 19 patients with MPNs.
Terra L. Lasho et al. Blood Adv 2018;2:
© 2018 by The American Society of Hematology

5. Survival data in 75 patients with blast phase MPN stratified by RUNX1 mutation and treatment strategy.
Survival data in 75 patients with blast phase MPN stratified by RUNX1 mutation and treatment strategy.
Terra L. Lasho et al. Blood Adv 2018;2:
© 2018 by The American Society of Hematology